Kimera Labs
Kimera Labs is a clinical-stage biotechnology laboratory in Miramar, Florida that produces pharmaceutical-grade placental MSC-derived exosomes and topical cosmetic lines (Kiara, Vive, Luxir) for aesthetic professionals and clinical researchers, operating from a 27,000 sq. ft. cGMP facility.
- Company typePrivate
- Founded2015
- HeadquartersMiramar Beach, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Kimera Labs does
Kimera Labs is a clinical-stage biotechnology laboratory headquartered in a 27,000 sq. ft. cGMP-certified facility in Miramar, Florida, specializing in the production of pharmaceutical-grade mesenchymal stem cell (MSC)-derived exosomes. Founded by Duncan Ross, Ph.D. and operating since 2012, the company isolates exosomes from cultured perinatal (placental) MSCs using a proprietary serial purification process and xeno-free, chemically defined media, distinguishing its workflow from tissue-processing or serum-based methods. The product portfolio spans commercial cosmetic topical lines — Kiara (hair vitality), Vive, and Luxir — alongside research-grade MSC exosomes and topical amino-acid ingredients marketed to aesthetic and clinical-research customers.
Technically, Kimera operates an advanced characterization stack to verify exosome identity and purity, including ONI STORM super-resolution fluorescence microscopy for tetraspanin biomarker visualization (CD9, CD63, CD81, CD73), Malvern NanoSight NS300 Nanoparticle Tracking Analysis, Agilent HPLC, Illumina NextSeq 1000 RNA sequencing, ELISA, AFM, and TEM. Manufacturing is conducted inside ISO 7 cleanrooms with ISO 5 laminar flow glovebox isolators under cGMP. The company holds an active FDA IND for a Phase I/IIa trial of its MSC exosomes in mild-to-moderate COVID-19 (Phase I safety readout targeted for Q3 2026) and has implemented ISO 9001:2015, ISO 13485:2016, and ISO 22716:2007 certifications, following closure of a September 2023 FDA Warning Letter tied to earlier unapproved products (XoGlo, XoGlo Pro, Amnio2X).
The business model is B2B and sales-led: products are sold to aesthetic professionals, dermatologists, oncologists, and medical researchers through inquiry-based engagement, facility tours, and on-campus educational seminars rather than consumer retail. Revenue is generated through one-time product sales of cosmetic lines and research-grade exosomes at undisclosed quote-based pricing. Geographic scope is currently USA-only, with no disclosed external funding rounds and no named institutional investors identified.
Kimera Labs firmographics
Firmographics- Name
- Kimera Labs
- Legal name
- Kimera Labs, Inc.
- Website
- https://kimeralabs.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Kimera Labs is a clinical-stage biotechnology laboratory in Miramar, Florida that produces pharmaceutical-grade placental MSC-derived exosomes and topical cosmetic lines (Kiara, Vive, Luxir) for aesthetic professionals and clinical researchers, operating from a 27,000 sq. ft. cGMP facility.
- Ownership category
- akta.pro rank
Kimera Labs industry classification
Industry- Product category
- Exosome Biotechnology Products
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)
Keywords
Where Kimera Labs is headquartered
LocationHeadquarters
- HQ city
- Miramar Beach
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Kimera Labs business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- MSC Exosome Product Sales: Sale of pharmaceutical-grade MSC-derived exosome products for cosmetic applications and clinical research. Products include Kiara (hair vitality), Vive (topical cosmetic), and research-grade exosomes sold to practitioners and medical facilities.
- Cosmetic Product Lines: Commercial topical cosmetic product lines including Kiara, Luxir, and Vive marketed to aesthetic professionals.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels7 records
Kimera Labs product offering
Product offeringCore offering
Kimera Labs produces pharmaceutical-grade, mesenchymal stem cell (MSC)-derived exosome products for cosmetic, aesthetic, and clinical/research applications. The company isolates and manufactures exosomes using proprietary processes in ISO 7 cleanroom, cGMP-compliant facilities, supplying aesthetic practitioners, medical facilities, and researchers with standardized biologic products.
Product overview
Kimera Labs operates as a clinical-stage biotechnology company specializing in placental mesenchymal stem cell (MSC)-derived exosome products. The company produces pharmaceutical-grade MSC exosomes from isolated cell cultures using chemically defined, xeno-free media in cGMP-compliant facilities. The product portfolio includes: (1) Kiara, a hair vitality cosmetic product; (2) Vive and Luxir, topical cosmetic product lines; (3) MSC Exosomes for research and clinical applications; and (4) amino acid ingredients for topical formulations. Previously marketed XoGlo, XoGlo Pro, and Amnio2X products have been discontinued following FDA regulatory action. The company holds an active IND with Phase I safety trials and is pursuing clinical development for dermatology and oncology applications.
Differentiator
Problem solved
Functional benefit
Brands
- Kiara: Hair vitality product utilizing placental MSC-derived extracellular vesicles for hair restoration.
- Vive
- Luxir
Products and services
- Kiara
- Vive
- Luxir
- MSC Exosomes
- Amino Acids (Topical)
Quantifiable outcome
- Successfully closed FDA Warning Letter issued September 1, 2023 after demonstrating corrective actions and ceasing unapproved product distribution during August 2024 follow-up inspection.
- +2 more outcomes
Companies that use Kimera Labs
Customer profileSegments4 records
Ideal customer profiles2 records
Kimera Labs technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
Kimera Labs partnerships and signals
Strategic signalScale indicators6 records
Recent moves6 records
Expansion highlights5 records
Kimera Labs competitors and assessment
Company assessmentMarket position
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Kimera Labs social profiles
Digital presenceKimera Labs compliance and trust
Trust signalCompliance4 records
Kimera Labs financial estimates
Financial estimateRevenue estimate
Valuation estimate
Kimera Labs leadership team
Management profileNumber of profiles
Profiles1 record
Kimera Labs funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Kimera Labs M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Kimera Labs
What does Kimera Labs do?
Kimera Labs produces pharmaceutical-grade, mesenchymal stem cell (MSC)-derived exosome products for cosmetic, aesthetic, and clinical/research applications. The company isolates and manufactures exosomes using proprietary processes in ISO 7 cleanroom, cGMP-compliant facilities, supplying aesthetic practitioners, medical facilities, and researchers with standardized biologic products.
Is Kimera Labs a public or private company?
Kimera Labs is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Kimera Labs founded?
Kimera Labs was founded in 2015. It employs 11 to 50 people.
Where is Kimera Labs based?
Kimera Labs is headquartered in Miramar Beach, United States, in the North America region.
How does Kimera Labs make money?
Two revenue lines are on record. MSC Exosome Product Sales are the primary driver. The others are cosmetic Product Lines.
Does Kimera Labs have an API?
No public API is recorded for Kimera Labs.
What industry is Kimera Labs in?
Kimera Labs's product category is Exosome Biotechnology Products. Its primary akta.pro industry code is HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived). Its NAICS code is 325414 and its SIC code is 2836.